BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology
ESPS manuscript NO: 13940
Title: Hepatitis C Virus: A global view
Reviewer's code: 02944188
Reviewer's country: Italy
Science editor: Xue-Mei Gong
Date sent for review: 2014-09-09 21:55
Date reviewed: 2014-09-24 00:59

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[Y] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[Y] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In the submitted work Amal et al aimed to review the situation of chronic hepatitis C, regarding diagnosis, prognosis and therapy. There are some major points to be addressed: 1. The authors should re-write the part regarding the antiviral therapy. They have not cited the last European and US guidelines regarding all the new direct antivirals. 2. The authors do not mention the possibility to use non-invasive methods to quantify chronic liver disease (such as fibroscan, or fibrotest, or ARFI) 3. The authors do not mention the utility of genetic markers (IL28B) to predict treatment response.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology
ESPS manuscript NO: 13940
Title: Hepatitis C Virus: A global view
Reviewer's code: 02944166
Reviewer's country: Germany
Science editor: Xue-Mei Gong
Date sent for review: 2014-09-09 21:55
Date reviewed: 2014-09-12 18:01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Sections and subheadings should be sorted: the section 'treatment' does, in parts, not really deal with treatment but rather with epidemiological issues - epidemiologigal data and e.g., distribution of genotypes might be shortened in favour of more information on new treatment options. Sofosbuvir is by far not the only DAA which is currently introduced into HCV therapy, also Simeprevir and Daclatasvir have been approved in many countries and a number of further substances are awaited. Authors might comment on these substances e.g., at least in a table - thorough editing by a native speaker is recommended.